UCB, a Belgium-based biopharmaceutical firm, has agreed to acquire Ra Pharmaceuticals, a United States-based clinical-stage biopharmaceutical company, it was reported on Friday.
The deal is valued at around USD2.1bn. According to the contract, Ra Pharmaceuticals shareholders will receive USD48 in cash for each share at closing.
Ra Pharma utilises an advanced peptide chemistry platform for the production of novel therapeutics to treat serious diseases caused by excessive or uncontrolled activation of the complement system. Ra Pharma's ExtremeDiversity platform facilitates the production of synthetic macrocyclic peptides through merging the diversity and specificity of antibodies with the pharmacological properties of small molecules. The company's phase 3 product candidate, Zilucoplan is a once-daily self-administered, subcutaneous peptide inhibitor of C5. It is being evaluated in phase 3 for the treatment of myasthenia gravis, an unpredictable and chronic auto-immune condition, in which auto-antibodies infect specific proteins in the neuro-muscular junction.
Sobi's Biologics License Application for NASP in uncontrolled gout accepted by FDA
Hydrosome Labs announces promising fermentation breakthrough with ultrafine bubbles
Ionis receives FDA Breakthrough Therapy designation for ION582 in Angelman syndrome
AMO Pharma signs licence agreement with PHRI and Venca Research Inc to advance new study in ARVC
Saol Therapeutics receives US FDA Complete Response Letter for SL1009 (DCA) in PDCD
Amgen and Kyowa Kirin release rocatinlimab study results in atopic dermatitis
Hemogenyx Pharmaceuticals partners with Made Scientific to advance CAR-T therapy
Lilly's Jaypirca delivers breakthrough results in front-line CLL trial